MX2020008323A - Composiciones farmacéuticas hipertónicas que contienen un agente quimioprotector antiplatino. - Google Patents

Composiciones farmacéuticas hipertónicas que contienen un agente quimioprotector antiplatino.

Info

Publication number
MX2020008323A
MX2020008323A MX2020008323A MX2020008323A MX2020008323A MX 2020008323 A MX2020008323 A MX 2020008323A MX 2020008323 A MX2020008323 A MX 2020008323A MX 2020008323 A MX2020008323 A MX 2020008323A MX 2020008323 A MX2020008323 A MX 2020008323A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
compositions containing
hypertonic pharmaceutical
platinum chemoprotectant
chemoprotectant agent
Prior art date
Application number
MX2020008323A
Other languages
English (en)
Inventor
John Lee
Qi- Ying HU
Fuxin Shi
Original Assignee
Decibel Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decibel Therapeutics Inc filed Critical Decibel Therapeutics Inc
Publication of MX2020008323A publication Critical patent/MX2020008323A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/02—Ammonia; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen composiciones farmacéuticas hipertónicas. Las composiciones farmacéuticas hipertónicas contienen un agente quimioprotector antiplatino y un agente gelificante. También se describen métodos de uso médico de las composiciones farmacéuticas hipertónicas.
MX2020008323A 2018-02-09 2019-02-08 Composiciones farmacéuticas hipertónicas que contienen un agente quimioprotector antiplatino. MX2020008323A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862628824P 2018-02-09 2018-02-09
PCT/US2019/017334 WO2019157370A1 (en) 2018-02-09 2019-02-08 Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent

Publications (1)

Publication Number Publication Date
MX2020008323A true MX2020008323A (es) 2020-10-14

Family

ID=67549759

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020008323A MX2020008323A (es) 2018-02-09 2019-02-08 Composiciones farmacéuticas hipertónicas que contienen un agente quimioprotector antiplatino.
MX2023001963A MX2023001963A (es) 2018-02-09 2020-08-07 Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023001963A MX2023001963A (es) 2018-02-09 2020-08-07 Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino.

Country Status (12)

Country Link
US (3) US10709732B2 (es)
EP (1) EP3749309A4 (es)
JP (2) JP7492917B2 (es)
KR (1) KR20200129107A (es)
CN (1) CN112020359A (es)
AU (1) AU2019218232A1 (es)
BR (1) BR112020016059A2 (es)
CA (1) CA3090783A1 (es)
IL (1) IL276569B2 (es)
MX (2) MX2020008323A (es)
SG (1) SG11202007595WA (es)
WO (1) WO2019157370A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017315679B2 (en) 2016-08-23 2023-12-14 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
WO2019157370A1 (en) 2018-02-09 2019-08-15 Decibel Therapeutics, Inc. Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent
US20220054640A1 (en) * 2018-12-11 2022-02-24 Decibel Therapeutics, Inc. Compositions and methods for the delivery of therapeutic agents across the round window membrane
US10813947B1 (en) 2019-05-31 2020-10-27 Decibel Therapeutics, Inc. Methods of otoprotection against platinum-based antineoplastic agents
WO2020256548A1 (en) * 2019-06-19 2020-12-24 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Sodium thiosulfate gel for preventing or reducing hearing loss
AU2020373113A1 (en) * 2019-10-30 2022-05-26 Otonomy, Inc. Otic formulations for drug-induced ototoxicity
MX2022010050A (es) 2020-02-21 2022-09-05 Akouos Inc Composiciones y metodos para tratar deficiencia auditiva no asociada con la edad en un sujeto humano.

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649621B2 (en) 1997-12-16 2003-11-18 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US6497902B1 (en) 1999-12-01 2002-12-24 The Regents Of The University Of Michigan Ionically crosslinked hydrogels with adjustable gelation time
AU5391901A (en) 2000-04-26 2001-11-07 Univ Oregon Health Sciences Administration of a thiol-based chemoprotectant compound
WO2003004505A1 (en) * 2001-07-02 2003-01-16 Debiopharm S.A. Oxaliplatin active substance with a very low content of oxalic acid
BR122018068450B8 (pt) 2004-10-12 2021-07-27 Fmc Biopolymer As dispositivo implantável compreendendo gel de alginato
ME01956B (me) 2005-09-28 2015-05-20 Auris Medical Ag Farmaceutske kompozicije za tretman poremećaja unutrašnjeg uva
JP2010509188A (ja) 2006-11-09 2010-03-25 武田薬品工業株式会社 医薬組成物
CA2721927C (en) * 2008-04-21 2014-01-28 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US20100016450A1 (en) 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US8784870B2 (en) 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
EP3213756A1 (en) 2009-07-08 2017-09-06 Hope Medical Enterprise, Inc. D.b.a. Hope Pharmaceuticals Sodium thiosulfate-containing pharmaceutical compositions
US20130045957A1 (en) 2011-02-18 2013-02-21 Otonomy, Inc. Prevention of and Recovery from Drug-Induced Ototoxicity
US10130514B2 (en) 2011-09-26 2018-11-20 Incube Labs, Llc System and method for delivery of a therapeutic agent to the inner ear
FR2992861B1 (fr) * 2012-07-09 2014-10-17 Probionov Utilisation de thiosulfate pour potentialiser l'effet anti-pathogene des lactobacilles
MX2017015236A (es) * 2015-05-28 2018-11-09 Baylor College Medicine Beneficios de la suplementacion con n-acetilcisteina y glicina para mejorar los niveles de glutation.
EP3331547A4 (en) 2015-08-05 2019-08-21 Children's Medical Center Corporation COMPOSITIONS WITH PERMEATION PROMOTERS FOR ACTIVE INJECTION
EP3413889A1 (en) 2016-02-10 2018-12-19 Cocoon Biotech Inc. Compositions including benzenesulfonamide-containing non-steroidal anti-inflammatory drugs silk fibroin and a gelling agent and uses thereof
CA3029281A1 (en) 2016-06-29 2018-01-04 Otonomy, Inc. Triglyceride otic formulations and uses thereof
US11020354B2 (en) 2017-01-19 2021-06-01 Otologic Pharmaceuticals, Inc. Formulations of n-acetylcysteine and uses thereof
US10596190B2 (en) 2017-11-29 2020-03-24 Oregon Health & Science University Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy
WO2019118330A1 (en) 2017-12-12 2019-06-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Thermoresponsive hydrogel containing polymer microparticles for controlled drug delivery to the ear
US11918653B2 (en) 2017-12-22 2024-03-05 Dompé Farmaceutici S.P.A. Triglyceride otic formulations and uses thereof
US10946443B2 (en) 2018-01-08 2021-03-16 Hamilton Sundstrand Corporation Removal of unfused powder from an additive-manufactured part using piezoelectric transducers
JP7497289B2 (ja) 2018-01-09 2024-06-10 ドンペ ファーマシューティシ エス．ピー．エー． 成長因子耳用製剤
WO2019154895A1 (en) 2018-02-08 2019-08-15 Strekin Ag Gel formulation for preventing or treating hearing loss
WO2019157370A1 (en) 2018-02-09 2019-08-15 Decibel Therapeutics, Inc. Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent
US20210186943A1 (en) 2018-04-25 2021-06-24 Otonomy, Inc. Otic formulations for drug-induced ototoxicity
IT201800006566A1 (it) 2018-06-21 2019-12-21 Composizione per prevenire e trattare disordini uditivi e vestibolari
MA53102A (fr) 2018-07-03 2022-05-11 Fennec Pharmaceuticals Inc Formulations de thiosulfate de sodium anhydre
US10813947B1 (en) 2019-05-31 2020-10-27 Decibel Therapeutics, Inc. Methods of otoprotection against platinum-based antineoplastic agents
WO2020256548A1 (en) 2019-06-19 2020-12-24 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Sodium thiosulfate gel for preventing or reducing hearing loss

Also Published As

Publication number Publication date
US20210308176A1 (en) 2021-10-07
CA3090783A1 (en) 2019-08-15
KR20200129107A (ko) 2020-11-17
CN112020359A (zh) 2020-12-01
JP2021513558A (ja) 2021-05-27
WO2019157370A1 (en) 2019-08-15
EP3749309A1 (en) 2020-12-16
BR112020016059A2 (pt) 2020-12-08
US11857567B2 (en) 2024-01-02
SG11202007595WA (en) 2020-09-29
JP2024098070A (ja) 2024-07-19
IL276569A (en) 2020-09-30
AU2019218232A1 (en) 2020-09-24
MX2023001963A (es) 2023-02-23
US20190336524A1 (en) 2019-11-07
US10709732B2 (en) 2020-07-14
IL276569B2 (en) 2023-06-01
US11071751B2 (en) 2021-07-27
JP7492917B2 (ja) 2024-05-30
EP3749309A4 (en) 2021-12-08
US20200338119A1 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
MX2023001963A (es) Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino.
MX2022001755A (es) Compuestos de dinucleotidos ciclicos y metodos de uso.
EP3840730A4 (en) COMPOSITIONS FOR DELIVERY OF THERAPEUTICS AND METHOD OF USE AND MANUFACTURING THEREOF
CR20200064A (es) Carboxamidas como moduladores de los canales de sodio
MX2019012978A (es) Composiciones para el cuidado bucal y metodos para utilizar las composiciones.
AU2018231044A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
MX2020007060A (es) Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
MX2022014457A (es) Formulaciones de inmunoconjugado anti-cd79b estables.
MX2019014772A (es) Formulaciones en gel de bisfosfocinas y usos de estas.
PH12019502548A1 (en) Pyrazole magl inhibitors
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
WO2018183631A8 (en) Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same
PH12018000077B1 (en) A pharmaceutical composition for neuropathic pain
UY36761A (es) Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma
ZA202001756B (en) Oral care compositions
MX2020011756A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
JOP20220160A1 (ar) مركبات فعّالة نحو مستقبلات نووية
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
WO2019043176A3 (en) HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
MX2018001989A (es) Formulaciones farmaceuticas.
MX2017010277A (es) Cenicriviroc para el tratamiento de la fibrosis.
ZA202102816B (en) High concentration protein formulation
MX2021010207A (es) Formulacion farmaceutica de liberacion extendida.